Literature DB >> 25892190

Age-related Differences in CYP3A Abundance and Activity in the Liver of the Göttingen Minipig.

Els Van Peer1, Lies De Bock2, Koen Boussery2, Jan Van Bocxlaer2, Christophe Casteleyn1, Chris Van Ginneken1, Steven Van Cruchten1.   

Abstract

In view of paediatric drug development, regulatory authorities often request safety studies in juvenile animals, including minipigs. Unfortunately, knowledge on the ontogeny of the biotransformation processes in animal models remains scarce and impedes a correct interpretation of the toxicity findings. CYP3A4 is one of the most important drug-metabolizing enzymes in human beings and shows important similarities with CYP3A in the minipig. Therefore, the aim of this study was to assess the abundance and activity of CYP3A in liver microsomes from foetal, juvenile (days 1, 3, 7 and 28) and adult male and female Göttingen minipigs. CYP3A abundance was studied by an indirect enzyme-linked immunosorbent assay (ELISA), whereas CYP3A activity was assessed by a biotransformation assay with Luciferin-IPA. CYP3A abundance could not be detected until day 3. From day 7 onwards, a gradual increase in expression was noted, leading to the highest abundance in adult animals. CYP3A activity was not detectable in foetuses and 1-day-old animals. The CYP3A activity was detectable, but below the LLOQ in day 3 animals and increased gradually with age to reach the highest level in adults. The CYP3cide and ketoconazole inhibition, and testosterone and midazolam reduction of Luciferin-IPA metabolism in minipig liver microsomes substantiate that Luciferin-IPA is metabolized by CYP3A in minipigs. A positive correlation was found between CYP3A abundance and biotransformation of Luciferin-IPA (Pearson r = 0.863; p < 0.0001). In conclusion, both abundance and activity of CYP3A increased gradually in juvenile minipigs, but remained below the levels observed in adult animals.
© 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25892190     DOI: 10.1111/bcpt.12410

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  8 in total

1.  Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.

Authors:  Els Van Peer; Noel Downes; Christophe Casteleyn; Chris Van Ginneken; Arie Weeren; Steven Van Cruchten
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-19       Impact factor: 2.745

2.  In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Authors:  Els Van Peer; Frank Jacobs; Jan Snoeys; Jos Van Houdt; Ils Pijpers; Christophe Casteleyn; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

Review 3.  Porcine cytochrome P450 3A: current status on expression and regulation.

Authors:  Martin Krøyer Rasmussen
Journal:  Arch Toxicol       Date:  2020-03-14       Impact factor: 5.153

4.  Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.

Authors:  Floriane Lignet; Eva Sherbetjian; Nicole Kratochwil; Russell Jones; Claudia Suenderhauf; Michael B Otteneder; Thomas Singer; Neil Parrott
Journal:  Pharm Res       Date:  2016-07-28       Impact factor: 4.200

5.  Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective.

Authors:  Wim Schelstraete; Laura De Clerck; Elisabeth Govaert; Joske Millecam; Mathias Devreese; Dieter Deforce; Jan Van Bocxlaer; Siska Croubels
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

Review 6.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 7.  The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development.

Authors:  Miriam Ayuso; Laura Buyssens; Marina Stroe; Allan Valenzuela; Karel Allegaert; Anne Smits; Pieter Annaert; Antonius Mulder; Sebastien Carpentier; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharmaceutics       Date:  2020-12-30       Impact factor: 6.321

8.  The Ontogeny of Cytochrome P450 Enzyme Activity and Protein Abundance in Conventional Pigs in Support of Preclinical Pediatric Drug Research.

Authors:  Joske Millecam; Laura De Clerck; Elisabeth Govaert; Mathias Devreese; Elke Gasthuys; Wim Schelstraete; Dieter Deforce; Lies De Bock; Jan Van Bocxlaer; Stanislas Sys; Siska Croubels
Journal:  Front Pharmacol       Date:  2018-05-14       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.